Day: December 11, 2021

– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model –  – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model – SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. Additionally, a published abstract in Blood reports on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma. NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed...

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation rate due to adverse reactions demonstrated in 24-week primary analysis1Data support longer-term use of Scemblix in patients with chronic myeloid leukemia (CML) who have previously struggled with intolerance and resistance to at least two prior tyrosine kinase inhibitor treatments2-4Differentiated by novel mechanism of action, Scemblix is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket2-4Clinical development program continues, evaluating Scemblix across multiple treatment lines in CML2-19Basel, December 11, 2021 — Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib)...

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December 11, 2021, at 7:30pm EST PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in high-grade B-cell lymphoma (HGBL), formerly referred to as double-hit lymphoma (DHL), and chronic lymphocytic leukemia (CLL), in two presentations at the 63rd American Society of Hematology (ASH) Annual Meeting held December 11-14, 2021 in Atlanta GA. “The data presented at ASH show that VIP152 has increased selectivity...

– Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile – – Phase 2 Clinical Trials in DLBCL and FL and Combination Clinical Trials to be Initiated –   – Company to Host Conference Call and Webcast Today at 7:30 p.m. EST – MOUNTAIN VIEW, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the presentation of clinical results from the Company’s Phase 1 trial evaluating IGM-2323, a novel bispecific IgM antibody targeting CD20 x CD3, at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The data was featured...

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1Median follow-up of approximately 17 months from the ELARA study showed a 67% one-year progression-free survival (PFS) rate in patients with r/r FL; for those who had a complete response, 12-month PFS was 86%1Remarkable safety profile remained consistent with initial analysis; no high-grade cytokine release syndrome was reported within eight weeks post-infusion and no new safety signals were identified1Basel, December 11, 2021 — Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular lymphoma (FL) based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase...

At SkiStar AB (publ)’s annual general meeting, held in Sälen on 11 December 2021, the following decisions were made.A dividend of SEK 1.50 per share was adopted. Record day 14 December 2021. Lena Apler, Sara Karlsson, Fredrik Paulsson, Gunilla Rudebjer and Anders Sundström were re-elected to the board and Anders Svensson and Vegard Søraunet were elected new members of the board. Anders Sundström was elected chairman of the board. Board fees, including committee fees, were raised to a total of SEK 2,410,000 (2020: SEK 1,900,000). The fees shall be distributed as follows: SEK 550,000 (550,000) to the chairman of the board and SEK 250,000 (220,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (200,000), distributed as follows: SEK 120,000 (100,000) to the committee chairman and...

Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in BALLI-01 Phase 1 Study The addition of Alemtuzumab to FC (FCA) Resulted in Prolonged Host-Lymphocyte Suppression, and UCART22 Expansion Preliminary Data Demonstrating Encouraging Anti-Leukemic Activity was Observed in 2 Patients BALLI-01 is Currently Enrolling at Dose Level Three with FCA (fludarabine, cyclophosphamide, alemtuzumab) Lymphodepletion Regimen Pre-Clinical Data from Cellectis’ Proprietary Product Candidate Talglobin01 Demonstrates that TALEN® Could Be Specific and Efficient at Correcting the Mutated Beta-Globin Gene that Causes Sickle Cell DiseaseNEW YORK, Dec. 11, 2021 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq:...

Press release   Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconciliation. Considering the very high acceptance rate, the Board of Directors has as of today resolved to complete the Share Swap Offer. Moreover, based on the very high acceptance rate, the Company’s Board of Directors has resolved to apply for a delisting of the Company’s shares from Nasdaq First North Growth Market Sweden (“Nasdaq First North”) in connection the change of marketplace related to the Company’s recapitalization and reorganization (“Recapitalization”) into a U.S. holding company (Allarity Therapeutics, Inc., a Delaware corporation) and...

Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, today will present positive data from its ADVANCE II Phase II study at the 63rd American Society of Hematology (ASH) Annual Meeting being held in Atlanta, Georgia from December 11-14, 2021. The Phase II data demonstrate the ability of DCP-001 to convert or significantly reduce detectable minimal residual disease (MRD) in acute myeloid leukemia (AML) patients, with fully converted patients demonstrating greater overall survival. The results of the trial also reinforced data from a preceding Phase I trial...

Figure 1Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4 Mutations– CXCR4 antagonism proof of concept established, with 100% overall response rate to combination treatment in frontline and refractory patients – – Median Serum IgM reductions in refractory CXCR4MUT patients on combination therapy similar to those seen in CXCR4WT patients on ibrutinib monotherapy – – Study enrollment ongoing at highest dose of mavorixafor; longer-term response data, dose selection, and regulatory updates expected in 2022 – BOSTON, Dec. 11, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with...